Generic Taxotere Availability
Last updated on May 7, 2025.
Taxotere is a brand name of docetaxel, approved by the FDA in the following formulation(s):
TAXOTERE (docetaxel - injectable;injection)
-
Manufacturer: SANOFI AVENTIS US
Approval date: May 14, 1996
Strength(s): 40MG/ML (discontinued) [RLD] -
Manufacturer: SANOFI AVENTIS US
Approval date: August 2, 2010
Strength(s): 80MG/4ML (20MG/ML) (discontinued) [RLD] -
Manufacturer: SANOFI AVENTIS US
Approval date: August 3, 2010
Strength(s): 20MG/ML (20MG/ML) (discontinued) [RLD] -
Manufacturer: SANOFI AVENTIS US
Approval date: April 13, 2012
Strength(s): 160MG/8ML (20MG/ML) [RLD] [AP]
Is there a generic version of Taxotere available?
Yes. The following products are equivalent to Taxotere:
docetaxel injectable;injection
-
Manufacturer: ACTAVIS
Approval date: September 21, 2015
Strength(s): 160MG/8ML (20MG/ML) [AP] -
Manufacturer: AMNEAL
Approval date: January 19, 2018
Strength(s): 160MG/8ML (20MG/ML) [AP] -
Manufacturer: HENGRUI PHARMA
Approval date: August 9, 2017
Strength(s): 160MG/8ML (20MG/ML) [AP] -
Manufacturer: HERITAGE
Approval date: November 26, 2024
Strength(s): 160MG/8ML (20MG/ML) [AP] -
Manufacturer: MYLAN LABS LTD
Approval date: April 1, 2019
Strength(s): 160MG/8ML (20MG/ML) [AP] -
Manufacturer: SHILPA
Approval date: May 16, 2019
Strength(s): 160MG/8ML (20MG/ML) [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Taxotere. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Taxotere (docetaxel)
- Check interactions
- Compare alternatives
- Reviews (11)
- Side effects
- Dosage information
- During pregnancy
- Drug class: mitotic inhibitors
- Breastfeeding
Patient resources
Other brands
Professional resources
Related treatment guides
Related/similar drugs
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Premarin
Premarin is used to treat symptoms of menopause such as hot flashes, and vaginal dryness. Learn ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AP | Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.